Overview
Exploring the effectiveness and safety of early use of Ariceptinfen after pancreaticoduodenectomy in alleviating postoperative pain and promoting recovery of patients.
Main objective: To explore the analgesic effect of Anricfen after pancreaticoduodenectomy.
Secondary objective: To explore the impact of Anricfen on the accelerated recovery after pancreaticoduodenectomy.
Exploratory objective: To investigate the biomarkers of Anricfen's analgesic effect after pancreaticoduodenectomy, as well as its correlation factors with tumor pathology.
Eligibility
Inclusion Criteria:
- Patients who underwent pancreatic surgery, including pancreaticoduodenectomy (PD), pancreatic-preserving pancreaticoduodenectomy (PPPD), and laparoscopic pancreaticoduodenectomy (LPD)
- Age ≥ 18 years old and \< 80 years old
- ASA Ⅰ-Ⅲ
- Be able to clearly understand and voluntarily participate in the research
Exclusion Criteria:
- Merging severe primary diseases involving the heart, brain, liver, kidneys and hematopoietic system
- History of long-term use of psychotropic drugs and cognitive dysfunction
- Having a history of acute poisoning from alcohol, sleeping pills, painkillers or other drugs that affect the central nervous system
- Pregnancy or lactation period
- History of allergy to NSAIDs, opioids, or to the test medication
- Drug users, alcoholics, and opiate abusers
- Those who had a history of chronic pain before the operation and a history of long-term use of analgesics and/or sedatives
- Those who had thyroid dysfunction before the operation
